PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
The company owns issued use-patents giving the right to treat diabetes and obesity with TRPV1 antagonists.
Our safe clinical development candidate, XEN-D0501, entered the first clinical trials in type-2 diabetic patients in 2017.
We are extremely proud to inform you that, as of today, our Opinion and Concept Paper on the role of TRPV1 in diabetes is finally published in Trends in Molecular Medicine!
Read the paper here
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here